Sign in
4

Changes in Ownership

Ultragenyx Pharmaceutical Inc. Filed Acc 0001209191-18-036501

CFO & Executive Vice President sold 6,700 shares at $80.07 ($536,456)

  • CFO & Executive Vice President acquired 3,350 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Sharp Shalini · CFO & Executive Vice President

Table I: Non-derivative

2 lines
Date Transaction Shares Price Value Owned after D/I
2018-06-07 Exercise or conversion : show line 1 in the form +3,350 $0.82 $2,730 60,178 D
2018-06-07 Sale : show line 2 in the form −6,700 $80.07 $536,456 53,478 D
Open-market sales · 6,700 sh · avg $80.07 · $536,456

Table II: Derivative

1 line
Date Transaction Shares Exercise Expires Underlying Owned after D/I
2018-06-07 Exercise or conversion : show line 3 in the form Stock Option (Right to Buy) −3,350 $0.82 2022-08-01 3,350 22,313 D
Loading xslF345X03/doc4.xml…